Ocular Myasthenia Gravis: Controversies and Updates
- 23 November 2013
- journal article
- review article
- Published by Springer Science and Business Media LLC in Current Neurology and Neuroscience Reports
- Vol. 14 (1), 1-10
- https://doi.org/10.1007/s11910-013-0421-9
Abstract
The majority of patients with myasthenia gravis (MG) initially present with ocular symptoms. An unresolved question is whether there are clinical features at onset to guide clinicians to predict an individual patient’s conversion risk from ocular MG (OMG) to generalized disease, or “secondary generalized MG” (SGMG), that is, a prognostic model. In light of the emerging theory that early corticosteroids may have a risk-modifying effect, the factors associated with secondary SGMG previously reported should be revisited. Studies showing potential risk-modifying effects of corticosteroids are useful, though flawed, owing to the heterogeneous retrospective studies and methods of reporting. Updates on other potential immunosuppressive agents are also discussed. Thymectomy in OMG has been recently reported in a few studies to be useful. MG associated with antibodies to muscle-specific kinase, usually associated with severe generalized MG, can cause a pure OMG syndrome. Recent serological developments in seronegative patients have also revealed antibodies to clustered anti-acetylcholine receptor and lipoprotein receptor-related protein-4.Keywords
This publication has 90 references indexed in Scilit:
- Women and Transplantation: Fertility, Sexuality, Pregnancy, ContraceptionAdvances in Chronic Kidney Disease, 2013
- Pure ocular anti‐musk myasthenia under no immunosuppressive treatmentMuscle & Nerve, 2013
- Extended Transsternal Thymectomy for the Treatment of Ocular Myasthenia GravisThe Annals of Thoracic Surgery, 2011
- A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravisBMC Neurology, 2011
- Muscle-Specific Receptor Tyrosine Kinase Antibody Positive Myasthenia Gravis Current StatusJournal of Clinical Neurology, 2009
- IgG1 antibodies to acetylcholine receptors in ‘seronegative’ myasthenia gravis†Brain, 2008
- Ocular myasthenia: a rare presentation with MuSK antibody and bilateral extraocular muscle atrophyBritish Journal of Ophthalmology, 2007
- Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatmentBritish Journal of Ophthalmology, 2005
- Timing of immunosuppression in the natural history of autoimmune diseaseJournal of Autoimmunity, 1992
- Preliminary Results of a Double-Blind, Randomized, Placebo-Controlled Trial of Cyclosporine in Myasthenia GravisNew England Journal of Medicine, 1987